Jitendra – Page 9 – Scilex Holding

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of changes in beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

15 Nov

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

14 Nov

SEC FIlings

Statement of acquisition of beneficial ownership by individuals – Amendment

November 17, 2022
Posted by Jitendra

Posts by Jitendra

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

Initial statement of changes in beneficial ownership of securities

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

Statement of acquisition of beneficial ownership by individuals – Amendment

Gloperba Launch – Nasdaq-2024

A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain

Gout Awareness Day – May 22

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch